Olink Proteomics

Olink Proteomics was founded to overcome the limitations of traditional proteomics, providing a platform for accurate, high-throughput protein analysis. Its core Proximity Extension Assay (PEA) technology achieved widespread adoption in major academic and pharmaceutical research, culminating in its 2024 acquisition by Thermo Fisher Scientific. The company's strategy focuses on enabling the entire biomarker pipeline, from large-scale discovery to the development of validated clinical signatures, now amplified by Thermo Fisher's global commercial and R&D infrastructure.

Proprietary Proximity Extension Assay (PEA) technology, which uses antibody pairs with DNA tags to create unique, amplifiable barcodes for each protein, enabling highly specific, sensitive, and multiplexed protein detection.

Competition includes SomaLogic (aptamer-based), Quanterix (ultra-sensitive immunoassays), and mass spectrometry platforms. Olink's differentiation lies in PEA's high specificity, scalability from discovery to targeted analysis, and, post-acquisition, the unparalleled commercial and R&D support of Thermo Fisher Scientific.